CHOSA Oncology AB initiates payment of last portion of loan given to RhoVac AB

CHOSA Oncology AB has initiated the payment of final portion of the loan of 10 MSEK and interest which RhoVac AB obtained from shareholders to support the development of RV001.

CEO Peter Buhl commenting: “After several administrative steps CHOSA has initiated the pay back process to fulfill our obligations towards the loan givers. I want to thank you all for your patience and for your support in developing products for hard-to-treat cancers.”

This disclosure contains information that Chosa Oncology AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 08-04-2023 10:31 CET.

For additional information contact:
Peter Buhl Jensen, CEO
pbj@buhloncology.com
+ 45 21 60 89 22

CHOSA in short
CHOSA Oncology AB is an oncology biotechnology company led by a proven international team with veteran specialists in oncology; drug development; running clinical trials; regulatory expertise; and business development. CHOSA intends to enter into agreements for partnership or sublicensing of iCIP™.